CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2, Randomized, Open-Label, Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05848011
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:29:08.175067+00:00
Published At: 2026-04-17T00:00:00+00:00
Record Updated At: 2026-04-17
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Androgen-Independent Prostatic Cancer", "Androgen-Independent Prostatic Neoplasms", "Prostate Cancer Recurrent", "Androgen-Insensitive Prostatic Cance", "Androgen-Resistant Prostatic Cancer", "Hormone Refractory Prostatic Cancer", "Immunotherapy", "Immune Checkpoint Inhibitor", "Inhibitory Checkpoint Molecule"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-17"
protocolSection.identificationModule.nctId: "NCT05848011"
protocolSection.identificationModule.officialTitle: "A Phase 2, Randomized, Open-Label, Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.